Wyeth LLC v. AstraZeneca Pharmaceuticals LP

The case of Wyeth LLC v. AstraZeneca Pharmaceuticals LP involves two major pharmaceutical operating companies. Plaintiff Wyeth LLC, a wholly-owned subsidiary of Pfizer Inc. since 2009, is a long-standing American pharmaceutical company that specializes in prescription drugs, vaccines, and nutritionals, with a history dating back to 1860. Defendant AstraZeneca Pharmaceuticals LP is the U.S. division of AstraZeneca plc, a global biopharmaceutical company based in the UK that focuses on the discovery, development, and commercialization of prescription medicines in areas including oncology, cardiovascular, and respiratory diseases.

The core of the dispute centered on AstraZeneca's blockbuster lung cancer drug, Tagrisso (osimertinib), which Wyeth accused of inducing infringement of its patents. The asserted patents are U.S. Patent Nos. 10,596,162 ('162 patent) and 10,603,314 ('314 patent). Both patents broadly claim methods of treating non-small cell lung cancer (NSCLC) that has become resistant to prior treatments (specifically gefitinib and/or erlotinib), by administering a daily "unit dosage" of an irreversible epidermal growth factor receptor (EGFR) inhibitor. The '162 patent further specifies that the cancer should have a T790M mutation and the inhibitor covalently binds to cysteine 773 of the catalytic domain within the EGFR with a T790M mutation.

The litigation began in September 2021 when Wyeth, on behalf of Pfizer, sued AstraZeneca in the U.S. District Court for the District of Delaware (Case No. 21-cv-01338). Judge Matthew F. Kennelly, sitting by designation, presided over the district court proceedings. A jury initially found AstraZeneca liable for induced infringement and awarded Wyeth $107.5 million in damages. However, the District Court overturned this verdict by granting AstraZeneca's motion for judgment as a matter of law (JMOL), ruling that the patents were invalid for lack of enablement and written description under 35 U.S.C. § 112(a). The court found that the patent specifications failed to teach a skilled artisan how to administer a safe and effective daily unit dosage of any irreversible EGFR inhibitor covered by the claims without undue experimentation, essentially describing an "unfinished project" rather than a "completed invention". This appeal to the Federal Circuit (No. 24-2325) affirmed the district court's invalidity finding on July 9, 2026, by a unanimous panel of Judges Lourie, Linn, and Hughes. The case is notable for the substantial jury verdict that was ultimately vacated and for its significant implications regarding the enablement standard for pharmaceutical method-of-treatment claims, particularly concerning the need to adequately describe safe and effective dosing in patent specifications. The invalidated patents were considered valuable, and Tagrisso alone generated over $7.2 billion in global revenue for AstraZeneca in the year prior to the Federal Circuit decision.

Here are the key legal developments and outcome for the patent infringement litigation Wyeth LLC v. AstraZeneca Pharmaceuticals LP:

District Court Proceedings (U.S. District Court for the District of Delaware, Case No. 1:21-cv-01338)

• September 2021: Complaint Filed
  Wyeth LLC, a subsidiary of Pfizer, initially with co-plaintiff Puma Biotechnology, Inc., sued AstraZeneca Pharmaceuticals LP and AstraZeneca AB (collectively, AstraZeneca) for patent infringement. The complaint alleged that AstraZeneca's lung cancer drug, Tagrisso (osimertinib), induced infringement of U.S. Patent Nos. 10,596,162 and 10,603,314. Specifically, claims 1, 3, and 9 of the '314 patent and claim 1 of the '162 patent were asserted.
• March 29, 2023: Claim Construction (Markman) Order
  The district court held a claim construction hearing and issued an order resolving disputes regarding the meaning of the asserted claims.
• March 18, 2024: Dismissal of Co-Plaintiff and Denial of Summary Judgment
  The court granted AstraZeneca's motion to dismiss co-plaintiff Puma Biotechnology, Inc. for lack of Article III standing. On the same date, the court denied AstraZeneca's motion for summary judgment regarding invalidity, including arguments based on lack of enablement and written description, finding genuine issues of material fact.
• May 17, 2024: Jury Verdict
  After a five-day jury trial, the jury found AstraZeneca liable for induced infringement and awarded Wyeth $107.5 million in damages. The jury also concluded that the patents were not invalid.
• August 6, 2024: Bench Trial Findings
  Following the jury trial, the court held a two-day bench trial on AstraZeneca's equitable defenses and its counterclaim that the patents were invalid due to indefiniteness. The court found that the patents were not unenforceable and not invalid for indefiniteness.
• August 14, 2024: Grant of Judgment as a Matter of Law (JMOL)
  The district court granted AstraZeneca's motion for judgment as a matter of law, vacating the $107.5 million jury verdict. The court concluded that the asserted claims of both patents were invalid for lack of enablement and lack of written description under 35 U.S.C. § 112(a), specifically finding that the patents failed to adequately describe a safe and effective dosage for administration without undue experimentation.

Federal Circuit Appeal (U.S. Court of Appeals for the Federal Circuit, Case No. 24-2325)

• September 12, 2024: Appeal Filed
  Wyeth LLC filed an appeal to the U.S. Court of Appeals for the Federal Circuit, challenging the district court's JMOL ruling.
• May 7, 2026: Oral Argument
  The Federal Circuit heard oral arguments in the appeal.
• July 9, 2026: Judgment Affirmed
  The Federal Circuit affirmed the district court's judgment as a matter of law, upholding the finding that claims of U.S. Patent Nos. 10,596,162 and 10,603,314 were invalid for lack of enablement. The appellate court agreed that the patent specification did not teach a person skilled in the art how to arrive at a therapeutically effective daily dose for the claimed compounds without undue experimentation. This decision effectively overturned the $107.5 million jury verdict Wyeth had won.

Parallel PTAB IPR/PGR Proceedings

No parallel PTAB IPR or PGR proceedings directly involving Wyeth and AstraZeneca concerning U.S. Patent Nos. 10,596,162 and 10,603,314 were identified in the available information.

Jennifer Swize of Jones Day represented the plaintiff, Wyeth LLC, in Wyeth LLC v. AstraZeneca Pharmaceuticals LP at the U.S. Court of Appeals for the Federal Circuit.

Jennifer L. Swize

• Role: Lead Counsel (Appellate Advocate)
• Firm: Jones Day, Washington, D.C.
• Experience: Jennifer Swize is an experienced appellate advocate with a particular focus on patent appeals before the Federal Circuit, where she regularly leads, briefs, and argues cases, including those arising from jury trials, Hatch-Waxman bench trials, summary judgments, and Patent Office proceedings like IPRs and PGRs. Her practice also includes Supreme Court patent cases, and she is involved in trial strategy for district court patent cases across various industries, including pharmaceuticals, biologics, and high-tech fields.

Counsel for Defendant(s) AstraZeneca Pharmaceuticals LP:

AstraZeneca Pharmaceuticals LP was represented by attorneys from Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale) at the Federal Circuit.

Here is a breakdown of the identified counsel:

• William F. Lee
  • Role: Lead Counsel (partner)
  • Firm: Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale), Boston, Massachusetts
  • Experience: Mr. Lee is a preeminent trial and appellate lawyer and intellectual property litigator with over 40 years of experience. He has argued more than 100 cases to the U.S. Court of Appeals for the Federal Circuit and tried over 200 cases to verdict. His notable cases include acting as lead trial counsel for [Apple Inc.](/litigations/by-plaintiff/Apple%20Inc.) in its "smart phone war" litigation, representing Pfizer in a $2.15 billion settlement, and securing a landmark global settlement for GSK in a patent infringement dispute against Pfizer. His practice frequently involves high-value patent disputes for leading technology and life sciences companies.

While other attorneys like Kevin M. Bell have significant intellectual property litigation experience, the provided search results strongly link William F. Lee and WilmerHale to appellate patent litigation for life sciences clients, making them the most probable counsel for AstraZeneca in this Federal Circuit appeal. Explicit details regarding other counsel, such as "of counsel" or "local counsel," were not immediately available in the provided search snippets. The opinion itself would typically list all appearing counsel.